An expert panel advised the FDA to expand the use of CAR-T therapy in blood cancer, voting in favor of Carvykti and Abecma for multiple myeloma patients. Despite concerns about side effects, the panel found that the benefits outweighed the risks, especially for patients who have not responded to initial treatments. Both drugs showed significant delays in disease progression compared to standard therapy in clinical trials. However, there were more deaths in the CAR-T group due to myeloma or side effects in the early months of the studies. Currently, the medicines are approved for patients who have tried four or more medications for myeloma.
Source link
FDA advisers back CAR-T cell therapies in blood cancer, despite concerns
